Please login to the form below

Not currently logged in
Email:
Password:

Merck joins forces with Ranbaxy

Merck & Co has entered into a new strategic product development deal with India's largest pharmaceutical company, Ranbaxy
Merck & Co has entered into a new strategic product development deal with India's largest pharmaceutical company, Ranbaxy.

The two companies have signed a five-year agreement to develop anti-bacterial and anti-fungal drug candidates. Ranbaxy will be responsible for medicines discovery and clinical development through to phase II trials, while Merck will handle approval and marketing.

"We believe that our philosophy of partnering with big pharma will continue to gather momentum as companies continue to recognise the strength and breadth of our R&D expertise and resources," said Malvinder Mohan Singh, chief executive officer and managing director of Ranbaxy.

Ranbaxy will receive an undisclosed cash payment for entering into the agreement and stand to earn more than $100m for achievement of research, development and regulatory approval milestones, in addition to substantial profits from product royalties.

Dr Mervyn Turner, senior vice-president of worldwide licensing and external research at Merck, said: "Collaborations with external partners, wherever in the world, are an integral and essential part of Merck's long-term strategy to build and expand its pipeline."

Deals between multinational companies and Indian-based pharma are on the increase with Ranbaxy in particular looking to extend its drive to discover novel drugs, having already entered into a significant research partnership with GlaxoSmithKline (GSK).

12th May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics